CTOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Kloeckner Metals - Americas

Kloeckner Metals - Americas is a prominent steel and metal distributor based in Roswell, Georgia. As the North American subsidiary of Klöckner & Co SE, it ranks as the fourth-largest metal service center in North America, operating around 50 locations across the U.S., Mexico, Canada, and Puerto Rico. The company serves approximately 8,000 metalworking businesses with a diverse portfolio of over 190,000 products, including carbon steel, stainless steel, and aluminum. The company offers extensive services beyond distribution, such as custom processing, warehousing, logistics solutions, and supply chain management. This comprehensive approach helps customers optimize production schedules and reduce lead times by providing materials close to their operations. Kloeckner Metals supports various industries, including automotive, construction, energy, and infrastructure, ensuring that its customers have access to the products and services they need for their projects.

| GrayMatter |

GrayMatter is an industrial technology company based near Pittsburgh, Pennsylvania, with regional offices in the U.S., Canada, and India. The company specializes in digital transformation and industrial automation solutions, serving major organizations in manufacturing, energy, food and beverage, pharmaceuticals, and utilities worldwide. GrayMatter offers a variety of services aimed at improving operational efficiency and digital capabilities. Their key offerings include advanced industrial analytics, which helps companies utilize data for better decision-making, and a brilliant operations strategy that supports digital transformation initiatives. They also focus on risk mitigation during the digital transformation process. GrayMatters family of brands includes E-Merge, HTSE, Automation & Control Concepts, and Phantom Technical Services, each providing specialized automation solutions across different industries. The company has grown through strategic mergers and acquisitions, enhancing its capabilities and expanding its client base. Notable clients include major companies like Nestlé Purina PetCare and Anheuser-Busch, showcasing GrayMatters strong presence in the industrial sector.

Proctor Loan Protector

Our lender-placed insurance, blanket insurance, and specialty insurance programs provide comprehensive coverage to financial institutions, government entities, property investors, and property & casualty agencies. Proctor Loan Protectors service solutions are powered by superior customer service, proprietary innovations, technology, and an experienced team. We perform insurance tracking, which includes policy procurement, mail processing, disbursement facilitation, and an award-winning borrower call center.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.